Position in EXEL
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$41,061,268
+$33,706,534 QoQ
Shares Held
754,664
+340.1% QoQ
Ownership
0.305%
of shares outstanding
% of Portfolio
2.30%
of 13F equity value
Holder Rank
#54
of 756 holders
Holding Since
Mar 2020
16 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capital Impact Advisors, LLC holds $41,061,268 across 1 Biotechnology name. EXEL ranks #1 (100.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
754,664 | $41,061,268 |
All Filings in EXEL
Export CSV
16 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $41,061,268 | 754,664 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $7,354,734 | 171,479 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $47,970,444 | 1,094,466 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $8,355,196 | 202,305 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,738,420 | 175,554 | Shares | Sole | 2025-08-18 | |
| 2025-03-31 | $7,443,404 | 201,609 | Shares | Sole | 2025-05-20 | |
| 2024-06-30 | $766,316 | 34,104 | Shares | Sole | 2024-08-16 | |
| 2024-03-31 | $1,018,230 | 42,909 | Shares | Sole | 2024-05-15 | |
| 2023-06-30 | $591,741 | 30,965 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $601,030 | 30,965 | Shares | Sole | 2023-05-23 | |
| 2022-12-31 | $1,050,603 | 65,499 | Shares | Sole | 2023-02-15 | |
| 2022-09-30 | $399,526 | 25,480 | Shares | Sole | 2022-11-22 | |
| 2022-06-30 | $1,016,786 | 48,837 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $570,875 | 25,182 | Shares | Sole | 2022-05-16 | |
| 2020-06-30 | $545,521 | 22,979 | Shares | Sole | 2020-08-17 | |
| 2020-03-31 | $2,320,498 | 134,756 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||